Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.
Rik Ossenkoppele,Willemijn J. Jansen,Gil D. Rabinovici,Dirk L. Knol,Wiesje M. van der Flier,Bart N.M. van Berckel,Philip Scheltens,Pieter Jelle Visser,Sander C.J. Verfaillie,Marissa D. Zwan,Sofie Adriaanse,Adriaan A. Lammertsma,Frederik Barkhof,William J. Jagust,Bruce L. Miller,Howard J. Rosen,Susan M. Landau,Victor L. Villemagne,Christopher C. Rowe,Dong Y. Lee,Duk L. Na,Sang W. Seo,Marie Sarazin,Catherine M. Roe,Osama Sabri,Henryk Barthel,Norman Koglin,John R. Hodges,Cristian E. Leyton,Rik Vandenberghe,Koen Van Laere,Alexander Drzezga,Stefan Förster,Timo Grimmer,Pascual Sánchez-Juan,José M. Carril,Vincent Mok,Vincent Camus,William E. Klunk,Ann D. Cohen,Philipp T. Meyer,Sabine Hellwig,Andrew B. Newberg,Kristian Steen Frederiksen,Adam S. Fleisher,Mark A. Mintun,David A. Wolk,Agneta Nordberg,Juha O. Rinne,Gaël Chételat,Alberto Lleó,Rafael Blesa,Juan Fortea,Karine Madsen,Karen M. Rodrigue,David J. Brooks +55 more
Reads0
Chats0
TLDR
Findings indicate the potential clinical utility of amyloid imaging for differential diagnosis in early-onset dementia and to support the clinical diagnosis of participants with AD dementia and noncarrier APOE ε4 status.Abstract:
Importance Amyloid-β positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non–AD dementia. Objective To use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes. Data Sources The MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies. Study Selection Case reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data. Data Extraction and Synthesis Data were provided for 1359 participants with clinically diagnosed AD and 538 participants with non–AD dementia. The reference groups were 1849 healthy control participants (with amyloid PET) and an independent sample of 1369 AD participants (with autopsy data). Main Outcomes and Measures Estimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) e4 status, using the generalized estimating equations method. Results The likelihood of amyloid positivity was associated with age and APOE e4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE e4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; n = 377) and to a lesser degree in APOE e4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; n = 593; P Conclusions and Relevance Among participants with dementia, the prevalence of amyloid positivity was associated with clinical diagnosis, age, and APOE genotype. These findings indicate the potential clinical utility of amyloid imaging for differential diagnosis in early-onset dementia and to support the clinical diagnosis of participants with AD dementia and noncarrier APOE e4 status who are older than 70 years.read more
Citations
More filters
Journal ArticleDOI
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Billy Dunn,Samantha Budd Haeberlein,David M. Holtzman,William J. Jagust,Frank Jessen,Jason Karlawish,Enchi Liu,José Luis Molinuevo,Thomas J. Montine,Creighton H. Phelps,Katherine P. Rankin,Christopher C. Rowe,Philip Scheltens,Eric Siemers,Heather M. Snyder,Reisa A. Sperling,Cerise L Elliott,Eliezer Masliah,Laurie M. Ryan,Nina Silverberg +23 more
TL;DR: This research framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms and envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD.
Journal ArticleDOI
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Bengt Winblad,Bengt Winblad,Philippe Amouyel,Sandrine Andrieu,Clive Ballard,Carol Brayne,Henry Brodaty,Angel Cedazo-Minguez,Bruno Dubois,David Edvardsson,David Edvardsson,Howard Feldman,Laura Fratiglioni,Giovanni B. Frisoni,Serge Gauthier,Jean Georges,Caroline Graff,Caroline Graff,Khalid Iqbal,Frank Jessen,Frank Jessen,Gunilla Johansson,Linus Jönsson,Miia Kivipelto,Miia Kivipelto,Martin Knapp,Francesca Mangialasche,René J. F. Melis,Agneta Nordberg,Agneta Nordberg,Marcel G. M. Olde Rikkert,Chengxuan Qiu,Thomas P. Sakmar,Thomas P. Sakmar,Philip Scheltens,Lon S. Schneider,Reisa A. Sperling,Lars O. Tjernberg,Gunhild Waldemar,Anders Wimo,Henrik Zetterberg,Henrik Zetterberg +41 more
TL;DR: This poster aims to demonstrate the efforts towards in-situ applicability of EMMARM, which aims to provide real-time information about the physical and cognitive properties of Alzheimer's disease and other dementias.
Journal ArticleDOI
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Rik Ossenkoppele,Rik Ossenkoppele,Rik Ossenkoppele,Daniel R. Schonhaut,Daniel R. Schonhaut,Michael Schöll,Michael Schöll,Samuel N. Lockhart,Nagehan Ayakta,Nagehan Ayakta,Suzanne L. Baker,James P. O'Neil,Mustafa Janabi,Andreas Lazaris,Averill Cantwell,Jacob W. Vogel,Miguel Santos,Zachary A. Miller,Brianne M. Bettcher,Brianne M. Bettcher,Keith A. Vossel,Joel H. Kramer,Maria Luisa Gorno-Tempini,Bruce L. Miller,William J. Jagust,William J. Jagust,Gil D. Rabinovici,Gil D. Rabinovici +27 more
TL;DR: Results are consistent with and expand upon findings from post-mortem, animal and cerebrospinal fluid studies, and suggest that the pathological aggregation of tau is closely linked to patterns of neurodegeneration and clinical manifestations of Alzheimer's disease.
Journal ArticleDOI
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
TL;DR: This review summarizes and highlights clinical aspects of several of the most commonly encountered neurodegenerative diseases, including AD, frontotemporal dementia (FTD) and its variants, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and Huntington's Disease (HD).
Journal ArticleDOI
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Clifford R. Jack,Heather J. Wiste,Stephen D. Weigand,Terry M. Therneau,Val J. Lowe,David S. Knopman,Jeffrey L. Gunter,Matthew L. Senjem,David T.W. Jones,Kejal Kantarci,Mary M. Machulda,Michelle M. Mielke,Rosebud O. Roberts,Prashanthi Vemuri,Denise A. Reyes,Ronald C. Petersen +15 more
TL;DR: The goal was to develop cut points for amyloid positron emission tomography (PET), tau PET, flouro‐deoxyglucose (FDG) PET, and MRI cortical thickness.
References
More filters
Journal ArticleDOI
“Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician
Marshal F. Folstein,Marshal F. Folstein,Susan E B Folstein,Susan E B Folstein,Paul R. McHugh,Paul R. McHugh +5 more
TL;DR: A simplified, scored form of the cognitive mental status examination, the “Mini-Mental State” (MMS) which includes eleven questions, requires only 5-10 min to administer, and is therefore practical to use serially and routinely.
Journal ArticleDOI
Quantifying heterogeneity in a meta‐analysis
TL;DR: It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
Journal ArticleDOI
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more
TL;DR: The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available.
Journal ArticleDOI
The Clinical Dementia Rating (CDR): Current version and scoring rules
Journal ArticleDOI
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Suzanne S. Mirra,Albert Heyman,Daniel W. McKeel,S. M. Sumi,Barbara J. Crain,L. M. Brownlee,Vogel Fs,James P. Hughes,van Belle G,Leonard Berg +9 more
TL;DR: The Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed a practical and standardized neuropathology protocol for the postmortem assessment of dementia and control subjects, which provides neuropathologic definitions of such terms as “definite Alzheimer's disease” (AD), “probable AD,” “possible AD” and “normal brain” to indicate levels of diagnostic certainty.
Related Papers (5)
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Billy Dunn,Samantha Budd Haeberlein,David M. Holtzman,William J. Jagust,Frank Jessen,Jason Karlawish,Enchi Liu,José Luis Molinuevo,Thomas J. Montine,Creighton H. Phelps,Katherine P. Rankin,Christopher C. Rowe,Philip Scheltens,Eric Siemers,Heather M. Snyder,Reisa A. Sperling,Cerise L Elliott,Eliezer Masliah,Laurie M. Ryan,Nina Silverberg +23 more
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling,Paul S. Aisen,Laurel A. Beckett,David A. Bennett,Suzanne Craft,Anne M. Fagan,Takeshi Iwatsubo,Clifford R. Jack,Jeffrey Kaye,Thomas J. Montine,Denise C. Park,Eric M. Reiman,Christopher C. Rowe,Eric Siemers,Yaakov Stern,Kristine Yaffe,Maria C. Carrillo,Bill Thies,Marcelle Morrison-Bogorad,Molly V. Wagster,Creighton H. Phelps +20 more
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
William E. Klunk,Henry Engler,Agneta Nordberg,Yanming Wang,G. Blomqvist,Daniel P. Holt,Mats Bergström,Irina Savitcheva,Guo Feng Huang,Sergio Estrada,Birgitta Ausén,Manik L. Debnath,Julien Barletta,Julie C. Price,Johan Sandell,Brian J. Lopresti,Anders Wall,Pernilla Koivisto,Gunnar Antoni,Chester A. Mathis,Bengt Långström +20 more